Funding translational research for aging interventions, such as the AKG trial costing $1-1.5 million, is a high-leverage investment for potentially adding a decade to lifespan.

“if you're sitting there and you're saying, "Look, I'd like to put a million dollars to work on something that would dramatically change, you know, adding a decade to life, you're way better off putting, in my opinion, you really are better off putting money into this type of translational research than you are into basic science or into, you know, pharma research that is tends to be a little bit more, you know, you're just you're not going to move.”